Anti-leukemic effect of azacitidine, a DNA methyltransferase inhibitor, on cell lines of myeloid leukemia associated with Down syndrome

Myeloid leukemia associated with Down syndrome (ML-DS) mostly develops from transient abnormal myelopoiesis (TAM), a preleukemic condition, and is associated with somatic mutations in the GATA1 gene [1 –9]. We have previously reported that genetic mutations associated with epigenetic regulators contribute to the progression of TAM to ML-DS [10,11]. Although patients with ML-DS are sensitive to cytarabine and demonstrate high event-free survival, treatment-related morbidity and mortality are high , and optimizing treatment intensity is challenging [12–16].

Source: Experimental Hematology - February 9, 2024 Category: Hematology Authors: Tatsuhiko Tanaka, Ko Kudo, Rika Kanezaki, Kentaro Yuzawa, Tsutomu Toki, Ryo Okuse, Akie Kobayashi, Tomohiko Sato, Takuya Kamio, Kiminori Terui, Etsuro Ito Tags: Article Source Type: research